Cefotetan

Summary

Cefotetan (CHEMBL474579) is an approved small-molecule antibacterial drug (ATC J01DC05); indicated across 3 conditions including bacterial infectious disease and cholecystitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01DC05
• Indications: 3 conditions
• Clinical trials: 4
• Chemistry: 575.6 Da · C17H17N7O8S4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL474579
Name	Cefotetan
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	53025
ChEBI	CHEBI:3499
ATC	J01DC05
Molecular formula	C17H17N7O8S4
Molecular weight	575.6
InChIKey	SRZNHPXWXCNNDU-RHBCBLIFSA-N

SMILES: CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)C4SC(=C(C(=O)N)C(=O)O)S4)OC)SC2)C(=O)O

IUPAC name: (6R,7S)-7-[[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietane-2-carbonyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

ChEBI definition: A semi-synthetic second-generation cephamycin antibiotic with [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl, methoxy and {[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino groups at the 3, 7α, and 7β positions, respectively, of the cephem skeleton. It is resistant to a wide range of β-lactamases and is active against a broad spectrum of aerobic and anaerobic Gram-positive and Gram-negative microorganisms.

Pharmacological roles (ChEBI): antibacterial drug.

Also known as: Cefotetan, ICI 156,834, Ici-156,834, ICI-156834, NSC-760045, cefotetan, SID56463651, CEFOTETAN, SID144204232

Parent form; salt/anhydrous children: CHEMBL1201098

Patent coverage: 4,008 distinct patent families (15,647 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Lethal(3)malignant brain tumor-like protein 1, DNA dC->dU-editing enzyme APOBEC-3A, DNA dC->dU-editing enzyme APOBEC-3G, Beta-lactamase, ATP-binding cassette sub-family C member 3.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
L3MBTL1	5.1	Potency	7943	nM	CHEMBL_ACT_4626352

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
cholecystitis	1	MONDO:0002155	HP:0001082
osteomyelitis	0	MONDO:0005246	EFO:0003102

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE2	2
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00090272	PHASE3	COMPLETED	A Single Dose of a Marketed Drug Being Studied for a New Indication to Treat Surgical Site Infection Following Colorectal Surgery as Compared to a Marketed Drug Approved for This Indication (0826-039)
NCT07318584	PHASE2	NOT_YET_RECRUITING	Cefotetan Therapy for Escherichia Coli Infections
NCT01220661	PHASE2	COMPLETED	Safety and Efficacy of One Dose Prophylactic Antibiotic in Laparoscopic Colorectal Surgery
NCT04726046	PHASE1	COMPLETED	Effectiveness of Prophylactic Antibiotics Therapy in Laparoscopic Cholecystectomy on Infection Rate

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).